Back to homepage

Tag "Crohn’s disease"

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going

Authors: Eleanor Liu, Nasar Aslam, Gaurav Nigam, Jimmy K Limdi

This narrative review summarizes the current literature regarding the mechanism of action of tofacitinib, data from registrational trials, emerging real-world evidence, and an overview of the most recent safety evidence. The authors explore evolving treatment paradigms and also present a brief overview of the next generation of JAK inhibitors in the pipeline.


Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors

Authors: Keira A Fieldhouse Bsc, Samantha Ukaibe BSc, Erika L Crowley BSc, MSc, Reena Khanna MD, MSc, FRCPC, Ashley O’Toole MD, MHSc, FRCPC, Melinda J Gooderham MD, MSc, FRCPC

This paper reviews all incident cases and exacerbations of IBD reported in the literature during widescale use of IL-17 inhibitors beyond the clinical trials.


Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms

Authors: Benjamin Crooks MA MBBS, Tom Barnes MBBS BSc, Jimmy K Limdi FRCP FACG

This review brings together data reported on VDZ to date for treatment of inflammatory bowel diseases, comprising Crohn’s disease (CD) and ulcerative colitis (UC).